Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib

Journal of the National Cancer Institute

Volumn 108, Issue 1, 2016, Pages

  Wong, Victor ^a   Pavlick, Dean ^b   Brennan, Tim ^b   Yelensky, Roman ^b   Crawford, John ^a   Ross, Jeffrey S ^b,c   Miller, Vincent A ^b   Malicki, Denise ^a   Stephens, Philip J ^b   Ali, Siraj M ^b   Ahn, Hyunah ^a  

^a RADY CHILDREN'S HOSPITAL   (United States)

^b FOUNDATION MEDICINE   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CRIZOTINIB; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; IFOSFAMIDE; LMNA PROTEIN; NTRK1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; VIMENTIN; VINCRISTINE; ANTINEOPLASTIC AGENT; LAMIN A; LMNA PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE A; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

BONE LESION; CASE REPORT; CONGENITAL DISORDER; CONGENITAL INFANTILE FIBROSARCOMA; DRUG RESPONSE; FIBROSARCOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; INFANT DISEASE; LETTER; LUNG METASTASIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA; SPINE METASTASIS; WIDE EXCISION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SECONDARY; SPINAL NEOPLASMS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; FIBROSARCOMA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FUSION; HUMANS; INFANT; LAMIN TYPE A; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR, TRKA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPINAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84956594380     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv307     Document Type: Letter

References (9)

1. Orbach D, Rey A, Cecchetto G, et al. Infantile fibrosarcoma: management based on the European experience. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:318-323.
2. Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PHB. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genetics. 1998;l18:184-187.
3. Rubin BP, Chen CJ, Morgan TW, et al. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol. 1998;153:1451-1458.
4. Sheng WQ, Hisaoka M, Okamoto S, et al. Congenital-infantile fibrosarcoma. A clinicopathologic study of 10 cases and molecular detection of the ETV6-NTRK3 fusion transcripts using paraffin-embedded tissues. Am J Clin Pathol. 2001;115:348-355.
5. Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31:1023-1031.
6. Wiesner T, He J, Yelensky R, et al. Kinase fusions are frequent in Spitz tumors and spitzoid melanomas. Nature Comm. 2014;5:3116.
7. Vaishnavi A, Capelletti M, Le AT, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013;19:1469-1472.
8. Taipale M, Krykbaeva I, Whitesell L, et al. Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Nat Biotechnol. 2013;31:630-637.
9. Doebele RC, Davis LE, Vaishnavi A, et al. An oncogenic NTRK fusion in a soft tissue sarcoma patient with response to the tropomyosin-related kinase (TRK) inhibitor LOXO-101. Cancer Disc. 2015; In press.